
Doxorubicin (dox) is an anticancer agent with adverse effects, such as cardiac injury. Fumarate, a tricarboxylic acid cycle metabolite, has been shown to ameliorate cardiac injury. This study investigated the possible cardioprotective action of fumarate in dox-induced cardiac injury. Male Wistar rats were divided into four groups (n=8); control (distilled water 10 ml/kg, po), dox (10 mg/kg, ip), dox (10 mg/kg, ip) + fumarate (50 mg/kg, po) and dox (10 mg/kg, ip) + fumarate (100 mg/kg, po). The animals were treated for 10 days and euthanized. Blood was withdrawn, the heart was excised and immediately frozen for biochemical and molecular analyses. Fumarate reduced serum levels of troponin-T (57.5 %, p<0.05) at 50 mg/kg and (55 % p<0.05) at 100 mg/kg in the dox group. Malondialdehyde formation was reduced from 69.6±3.6 mmol/mg in the dox group to 52.4±3.4 nmol MDA/mg protein at 50 mg/kg and 39.4±0.9 nmol MDA/mg protein at 100 mg/kg in fumarate-treated dox rats (p<0.001). Similarly, catalase (CAT) (9-fold), superoxide dismutase (SOD) (3-fold), and glutathione peroxidase (GPx) (3-fold) activity, which was significantly decreased in the dox group, was reversed by fumarate at 100 mg/kg. Transforming growth factor (TGF) β1 expression was reduced by fumarate (p<0.001). The expression of endothelial nitric oxide synthase (eNOS) was reduced with the administration of fumarate at 100 mg/kg (26.2±1.6, p<0.001) in dox-treated rats. The data have shown that fumarate ameliorated the dox-induced cardiomyopathy by increasing CAT, SOD, and GPx activities and a reduction in TGFβ1 and eNOS expression.
The primary objective of this article is to present the potential biomedical applications of hydroxyapatite-based materials coated with polymers, as well as the methods used for producing such polymer coatings. Hydroxyapatite (HA) is an inorganic component of bone, distinguished by its high biocompatibility, bioactivity, and ability to integrate with bone tissue. However, its limited mechanical strength poses a barrier to broader clinical application. A solution to this issue involves coating HA with polymeric layers—both synthetic and natural—which enhances its physicochemical properties, increases resistance to compression and fracture, and enables surface functionalization. The article outlines various coating techniques, categorized into physical and chemical methods. It also discusses examples of applications for these materials, including controlled drug delivery systems, bone tissue engineering, and gene delivery. Owing to its surface modification capabilities and favorable properties, polymer-coated HA may serve as a basis for advanced implants and drug carriers. Furthermore, the article highlights the use of HA-polymer composites for coating metallic implants, which significantly improves their corrosion resistance and enhances bioactivity. The entire study is based on a review of scientific literature that identifies current trends and research directions in the development of modern HA-based biomaterials.
This study investigates the molecular docking interactions and antioxidant activity of an isolated bioactive compound from Stevia rebaudiana leaves, highlighting its potential as an antioxidant and anti-inflammatory agent. Stevia rebaudiana has been extensively studied for its medicinal properties, particularly in managing oxidative stress-related conditions. A bioactive compound (Rebaudioside A) was isolated using ethanol extraction, followed by phytochemical screening, TLC, column chromatography, and FTIR, NMR, and mass spectroscopy for identification. Molecular docking with nuclear factor kappa B (NF-κB) was performed using Schrödinger Suite, and antioxidant activity was assessed through 2,2-Diphenyl-1-picrylhydrazyl (DPPH) and 2,2′-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) assays. The isolated compound, Rebaudioside A, exhibited strong binding affinity with NF-κB (XP Gscore: -12.677), indicating significant anti-inflammatory potential. The compound showed moderate antioxidant activity, with DPPH radical scavenging activity (RSA) of 16.60% and ABTS RSA of 9.635%, while Trolox Equivalent Antioxidant Capacity (TEAC) values of 17.54 μmol/mg (DPPH) and 28.393 μmol/mg (ABTS). Therefore, we concluded that, Rebaudioside A demonstrates notable antioxidant and anti-inflammatory potential, suggesting its suitability for further pharmacological exploration in managing oxidative stress-related disorders.
Aim of the Study: the primary objective of this study was to assess, based on the results of a questionnaire-based survey, pharmacists’ communication skills when interacting with patients experiencing hearing loss of varying severity. The secondary objective was to evaluate pharmacists’ knowledge—derived from the collected responses—regarding the risk factors associated with hearing loss, including: comorbidities (e.g., diabetes, hypertension), pharmacotherapy involving ototoxic medications, patient age (e.g., age over 65 years). Materials and Methods: the study received approval from a bioethics committee. It was a prospective, anonymous, questionnaire-based study conducted among 130 pharmacists. The survey was distributed both online and in person (in printed form) and was targeted at pharmacists employed in community pharmacies. The questionnaire was created using Google Forms and distributed in two formats: printed (for in-person completion) and as an interactive online form. It contained 19 questions, 18 of which were closed-ended, while the final question was open-ended. Among the 18 closed questions, 14 were single-choice and 4 were multiple-choice. The first group of questions (Questions 1–7 and Question 19) pertained to pharmacists’ communication skills. The second group (Questions 8–10 and Question 16) focused on adverse drug reactions related to ototoxicity and pharmacists’ knowledge of patient groups at increased risk for hearing loss. The third group (Questions 11–15 and Question 17) addressed educational materials (including training) and technologies that facilitate communication with individuals who are hard of hearing. The open-ended Question 18 asked participants to propose solutions to support and improve communication between pharmacists and hard-of-hearing patients in community pharmacy settings. Results: findings from the 130 participating pharmacists indicate that the majority (52.3%) believe their current training has not adequately prepared them to work with hearing-impaired patients. One-third of respondents emphasized that information on adverse effects impacting hearing should be more clearly highlighted in materials provided by pharmacists, indicating the need for tailored communication regarding drugs with potential ototoxicity. A need for adaptation of educational materials to better suit hearing-impaired patients was also noted. A total of 49.2% of respondents rated their own communication skills with hearing-impaired patients as average, while approximately 28.5% rated them as poor. Conclusions: Based on the collected data, pharmacists assess their communication skills with hearing-impaired patients as insufficient. They correctly identify medicinal products that may cause hearing loss as an adverse effect and are able to point out patient groups whose underlying conditions increase the risk of hearing impairment. However, deficiencies in education (particularly in soft skills), training, and access to materials or equipment that facilitate communication with hearing-impaired patients are identified as the main barriers and challenges to effective communication in community pharmacy settings.
The formulation base plays a critical role in the physicochemical stability and therapeutic efficacy of dermatological creams. Vitamins A and C are widely used in skincare due to their anti-aging and antioxidant properties, yet they are chemically unstable and highly sensitive to environmental conditions. This study aimed to evaluate the impact of different pharmaceutical and dermocosmetic cream bases on the physical stability and rheological behavior of formulations containing selected forms of vitamin A (retinol, retinyl palmitate, solubilized form of retinyl palmitate) and vitamin C (ascorbic acid). Methods: Creams were prepared using four bases: two traditional (Lekobaza, Eucerin) and two modern dermocosmetic bases (Versatile, Emolivan). Physical stability parameters including centrifuge test, spreadability, droplet size in optical microscopy, and rheological properties were assessed at days 1, 7, 14, and 30. Droplet size changes were analyzed statistically using the Friedman test and Kendall’s W. Results: Creams formulated on Lekobaza and Eucerin maintained stability throughout 30 days. Versatile formulations showed good short-term stability (up to 14 days), but decreased viscosity and signs of destabilization by day 30. Emolivan was stable for retinol and solubilized vitamin A but showed rheological anomalies when combined with retinyl palmitate or ascorbic acid. Rheological analysis confirmed pseudoplastic flow behavior and time-dependent viscosity changes, particularly in Versatile and Emolivan systems. Conclusion: The choice of formulation base significantly affects the physical stability and usability of creams containing unstable vitamins. Traditional pharmaceutical bases provided superior long-term stability, while modern cosmetic bases may require formulation adjustments to maintain vitamin integrity.